伊布利特转复心房颤动的疗效及安全性评价

目的 评价伊布利特转复心房颤动的有效性和安全性.方法 入选31例持续时间＜90 d的阵发性和持续性心房颤动患者,15例静脉注射伊布利特进行转律,16例应用胺碘酮转律.比较两组药物转复心房颤动的成功率、转复时间和不良事件.结果 伊布利特组转复房颤的总成功率显著高于胺碘酮组(66.7与37.5％,x2=1.98,P＜0.05),伊布利特组的转复房颤时间明显缩短(31.75±7.39) min与(51.87±9.26) min,t =3.67,P＜0.05],未发生有临床意义的药物致心律失常作用.结论 伊布利特转复阵发性和持续性心房颤动优于胺碘酮,并有良好的安全性.

Efficacy and safety of ibutilide for conversion of atrial fibrillation

Objective To evaluate the efficacy and safety of ibutilide for conversion of paroxysmal and persistent atrial fibrillation. Methods 31 patients with atrial fibrillation duration less than 90 clays were included into amiodrone or ibutilide group. 16 patients were intravenously administer with amiodrone and 15 patients with ibutilide separately. Conversion rate, time needed to converse and adverse effects were compared between two groups. Results The total conversion rate of ibutilide group was significantly higher than that of amiodrone group（66.7% vs 37.5% ,X^2 = 1.98 ,P 〈0.05）. Time needed to converse was significantly shortened in ibutilide group compared with amiodrone group （ 31.75 ± 7.39 ） rain vs （ 51.87 ± 9.26 ） min, t = 3.67, P 〈 0.05 ]. No clinical significant adverse effects were observed in ibutilide group. Conclusion Intravenous administration of ibutilide in cardioversion of parox- ysmal and persistent atrial fibrillation was more safe and effective than amiodrone.